A multicenter, randomized, double-blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson's Disease. - ND A multicenter, randomized, double-blind, parallel-group placebo and pramipexole controlled study to ...
A multicenter, randomized, double-blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parkinson's Disease. - ND A multicenter, randomized, double-blind, parallel-group placebo and pramipexole controlled study to ...
A multicenter, randomized, double-blind, placebo-controlled, ascending dose, parallel group study exploring effects of SLV308 up to 42 mg/day administered as an adjunctive therapy to l-dopa in patients with advanced stage Parkinson’s disease A multicenter, randomized, double-blind, placebo-controlled, ascending dose, parallel group study ex ...
A multicenter, randomized, double-blind, placebo-controlled, ascending dose, parallel group study exploring effects of SLV308 up to 42 mg/day administered as an adjunctive therapy to l-dopa in patients with advanced stage Parkinson’s disease A multicenter, randomized, double-blind, placebo-controlled, ascending dose, parallel group study ex ...